Search Within

Steven M Horwitz

Formats
  1. Meeting Abstract (374)
  2. Journal Article (248)
  3. Review (13)
  4. Guidelines (11)
  5. Research Letter (9)
  6. Book Section (6)
  7. Correspondence (5)
  8. Editorial (4)
  9. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (671)
  2. Department of Medicine (671)
  3. Hematologic Malignancies, Division of (671)
  4. Lymphoma (671)
  5. Population Sciences Research Program (671)
  6. Survivorship Research (173)

More Groups

People
  1. Alison Moskowitz (235)
  2. Andrew Zelenetz (169)
  3. Paul Hamlin (140)
  4. Ariela Noy (139)
  5. David Straus (122)
  6. Maria Palomba (112)

More People

Years
  1. 2025 (18)
  2. 2024 (51)
  3. 2023 (41)
  4. 2022 (34)
  5. 2021 (53)
  6. 2020 (52)

More Years

Publications
  1. Blood (255)
  2. Journal of Clinical Oncology (64)
  3. Hematological Oncology (38)
  4. Blood Advances (19)
  5. Leukemia and Lymphoma (19)
  6. Annals of Oncology (18)

More Publications

Publishers
  1. American Society of Hematology (277)
  2. American Society of Clinical Oncology (65)
  3. Wiley Blackwell (55)
  4. Elsevier Inc. (34)
  5. Oxford University Press (25)
  6. Taylor & Francis Group (23)

More Publishers

Results (671)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 study of CFT7455, a novel degrader of IKZF1/3, in multiple myeloma and non-Hodgkin lymphoma
    Meeting Abstract

    Berdeja, J.; Ailawadhi, S.; Horwitz, S. M.; Matous, J. V.; Mehta-Shah, N.; Martin, T.; Muchtar, E.; Richardson, P. G.; Richard, S.; Bhutani, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Selective STAT3 degraders dissect peripheral T-cell lymphomas vulnerabilities empowering personalized regimens
    Meeting Abstract

    Astone, G.; Cappelli, L. V.; Chiu, W.; Kayembe, C.; Wang, R.; Yang, B.; Sharma, K.; Dey, J.; Karnik, R.; Brambilla, L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • ECHELON-2, (NCT01777152), 5-year results of a randomised, double-blind, phase 3 study of frontline brentuximab vedotin plus CHP vs CHOP in patients with CD30-positive peripheral T-cell lyphoma
    Meeting Abstract

    Trümper, L.; O'Connor, O. A.; Pro, B.; Illidge, T.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: Final data
    Journal Article

    Horwitz, S. M.; Scarisbrick, J. J.; Dummer, R.; Whittaker, S.; Duvic, M.; Kim, Y. H.; Quaglino, P.; Zinzani, P. L.; Bechter, O.; Eradat, H.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial
    Journal Article

    Horwitz, S.; Zinzani, P. L.; Bagot, M.; Kim, Y. H.; Moskowitz, A. J.; Porcu, P.; Dwyer, K.; Sun, W.; Herr, F. M.; Scarisbrick, J.
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Khimani, F.; Shustov, A. R.; Shadman, M.; Ruan, J.; Moskowitz, A. J.; Straus, D. J.; Kumar, A.; Sauter, C. S.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial
    Meeting Abstract

    Musiek, A. C. M.; Whittaker, S.; Horowitz, S. M.; Bagot, M.; Huen, A.; Fisher, D. C.; Haun, P.; Vermeer, M. H.; Ito, T.; Dwyer, K.; more...
    European Journal of Cancer (2021)

    Fulltext@MSK | Save
  • Time-to-next-treatment and time-to-next-systemic treatment in patients included in the PROCLIPI registry
    Meeting Abstract

    Quaglino, P.; Ortiz-Romero, P.; Bagot, M.; Cozzio, A.; Evison, F.; Geskin, L.; Guenova, E.; Hodak, E.; Horwitz, S.; Papadavid, E.; more...
    European Journal of Cancer (2021)

    Fulltext@MSK | Save
  • Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part I: Clinical and histologic features and diagnosis
    Review

    Stoll, J. R.; Willner, J.; Oh, Y.; Pulitzer, M.; Moskowitz, A.; Horwitz, S.; Myskowski, P.; Noor, S. J.
    Journal of the American Academy of Dermatology (2021)

    Fulltext@MSK | Save